Multidimensional Impact of Mediterranean Diet on IBD Patients.
Adult
Biomarkers
/ metabolism
C-Reactive Protein
/ analysis
Colitis, Ulcerative
/ complications
Crohn Disease
/ complications
Diet, Mediterranean
Fatty Liver
/ diet therapy
Feces
/ chemistry
Female
Humans
Leukocyte L1 Antigen Complex
/ analysis
Lipids
/ blood
Male
Middle Aged
Nutritional Status
Prospective Studies
Quality of Life
Treatment Outcome
Mediterranean diet
inflammatory bowel disease
liver steatosis
quality of life
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
30
01
2020
pubmed:
23
5
2020
medline:
16
11
2021
entrez:
23
5
2020
Statut:
ppublish
Résumé
Malnutrition with the accumulation of fat tissue and nonalcoholic fatty liver disease (NAFLD) are conditions associated with inflammatory bowel disease (IBD). Visceral fat and NAFLD-related liver dysfunction can both worsen intestinal inflammation. Because the Mediterranean diet (Md) has been shown to ameliorate both obesity and NAFLD, the aim of this study was to analyze the impact of Md on the nutritional state, liver steatosis, clinical disease activity, and quality of life (QoL) in IBD patients. Patients with IBD, both Crohn's disease (CD) and ulcerative colitis (UC), followed Md for 6 months. Their body mass index (BMI), body tissue composition, liver steatosis and function, serum lipid profile, clinical disease activity, and inflammatory biomarkers (C-reactive protein and fecal calprotectin) were collected at baseline (T0) and compared with those obtained after 6 months (T180) to evaluate the impact of Md. One hundred forty-two IBD patients, 84 UC and 58 CD, followed Md for 6 months. At T180, diet-adherent CD and UC improved BMI (UC -0.42, P = 0.002; CD -0.48, P = 0.032) and waist circumference (UC -1.25 cm, P = 0.037; CD -1.37 cm, P = 0.041). Additionally, the number of patients affected by liver steatosis of any grade was significantly reduced in both groups (UC T0 31 of 84 [36.9%] vs T180 18 of 84 [21.4%], P = 0.0016; CD T0 27 of 58 [46.6%] vs T180 18 of 58 [31.0%], P < 0.001) after dietary intervention. Finally, after 6 months of the diet, fewer UC and CD patients with stable therapy had active disease (UC T0 14 of 59 [23.7%] vs T180 4 of 59 [6.8%], P = 0.004; CD T0 9 of 51 [17.6%] vs T180 2 of 51 [3.0%], P = 0.011) and elevated inflammatory biomarkers. Mediterranean diet improved QoL in both UC and CD, but neither serum lipid profile nor liver function were modified by the diet. A significant reduction of malnutrition-related parameters and liver steatosis was observed in both CD and UC patients after short-term dietary intervention based on the adoption of Md, and this was associated with a spontaneous improvement of disease activity and inflammatory markers.
Sections du résumé
BACKGROUND & AIMS
Malnutrition with the accumulation of fat tissue and nonalcoholic fatty liver disease (NAFLD) are conditions associated with inflammatory bowel disease (IBD). Visceral fat and NAFLD-related liver dysfunction can both worsen intestinal inflammation. Because the Mediterranean diet (Md) has been shown to ameliorate both obesity and NAFLD, the aim of this study was to analyze the impact of Md on the nutritional state, liver steatosis, clinical disease activity, and quality of life (QoL) in IBD patients.
METHODS
Patients with IBD, both Crohn's disease (CD) and ulcerative colitis (UC), followed Md for 6 months. Their body mass index (BMI), body tissue composition, liver steatosis and function, serum lipid profile, clinical disease activity, and inflammatory biomarkers (C-reactive protein and fecal calprotectin) were collected at baseline (T0) and compared with those obtained after 6 months (T180) to evaluate the impact of Md.
RESULTS
One hundred forty-two IBD patients, 84 UC and 58 CD, followed Md for 6 months. At T180, diet-adherent CD and UC improved BMI (UC -0.42, P = 0.002; CD -0.48, P = 0.032) and waist circumference (UC -1.25 cm, P = 0.037; CD -1.37 cm, P = 0.041). Additionally, the number of patients affected by liver steatosis of any grade was significantly reduced in both groups (UC T0 31 of 84 [36.9%] vs T180 18 of 84 [21.4%], P = 0.0016; CD T0 27 of 58 [46.6%] vs T180 18 of 58 [31.0%], P < 0.001) after dietary intervention. Finally, after 6 months of the diet, fewer UC and CD patients with stable therapy had active disease (UC T0 14 of 59 [23.7%] vs T180 4 of 59 [6.8%], P = 0.004; CD T0 9 of 51 [17.6%] vs T180 2 of 51 [3.0%], P = 0.011) and elevated inflammatory biomarkers. Mediterranean diet improved QoL in both UC and CD, but neither serum lipid profile nor liver function were modified by the diet.
CONCLUSIONS
A significant reduction of malnutrition-related parameters and liver steatosis was observed in both CD and UC patients after short-term dietary intervention based on the adoption of Md, and this was associated with a spontaneous improvement of disease activity and inflammatory markers.
Identifiants
pubmed: 32440680
pii: 5841910
doi: 10.1093/ibd/izaa097
pmc: PMC7737160
doi:
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Lipids
0
C-Reactive Protein
9007-41-4
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Clin Nutr ESPEN. 2019 Aug;32:61-69
pubmed: 31221292
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
BMC Microbiol. 2011 Jan 10;11:7
pubmed: 21219646
Can J Gastroenterol Hepatol. 2015 Mar;29(2):77-84
pubmed: 25803017
Nutrients. 2019 Jun 20;11(6):
pubmed: 31226790
Inflamm Bowel Dis. 2011 Oct;17(10):2162-8
pubmed: 21910178
Inflamm Bowel Dis. 2019 Jan 1;25(1):124-133
pubmed: 29889226
Mediators Inflamm. 2019 Jun 24;2019:7659509
pubmed: 31341422
EMBO Mol Med. 2019 Feb;11(2):
pubmed: 30591521
Eur J Nutr. 2020 Apr;59(3):1115-1121
pubmed: 31006053
Am J Gastroenterol. 2017 Dec;112(12):1832-1839
pubmed: 29063908
J Lipids. 2014;2014:182575
pubmed: 24701352
Clin Nutr. 2014 Aug;33(4):678-83
pubmed: 24064253
Public Health Nutr. 2011 Dec;14(12A):2274-84
pubmed: 22166184
Nature. 2016 Jul 06;535(7610):75-84
pubmed: 27383982
Nature. 2013 Dec 19;504(7480):451-5
pubmed: 24226773
Gut. 2016 Nov;65(11):1812-1821
pubmed: 26416813
Ann Nutr Metab. 2019;74(1):18-23
pubmed: 30485836
Inflamm Bowel Dis. 2015 Oct;21(10):2311-9
pubmed: 26236952
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Gastroenterology. 2002 Sep;123(3):689-99
pubmed: 12198693
Eur J Clin Nutr. 2012 Mar;66(3):360-8
pubmed: 21847137
Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):133-46
pubmed: 25645969
Gastroenterology. 2015 May;148(6):1244-60.e16
pubmed: 25575572
Hum Genomics. 2013 Nov 27;7:24
pubmed: 24283712
Gastroenterology. 2008 Jul;135(1):173-84
pubmed: 18514073
Gut. 2012 Jan;61(1):86-94
pubmed: 21930728
J Gen Intern Med. 2000 Nov;15(11):789-96
pubmed: 11119171
Cell Metab. 2016 Jul 12;24(1):41-50
pubmed: 27320064
J Hepatol. 2013 Jul;59(1):138-43
pubmed: 23485520
J Multidiscip Healthc. 2016 Mar 07;9:103-9
pubmed: 27022273
PLoS One. 2015 Sep 29;10(9):e0139310
pubmed: 26418083
Front Immunol. 2019 Sep 19;10:2233
pubmed: 31608059
Gastroenterology. 2002 Sep;123(3):745-50
pubmed: 12198701
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2816-2818
pubmed: 30876963
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121
pubmed: 27899815
J Hepatol. 2019 Dec;71(6):1216-1228
pubmed: 31419514
Gut. 2020 Sep;69(9):1637-1644
pubmed: 31900290
Diabetes Metab. 2012 Dec;38(6):538-43
pubmed: 23182460
J Hepatol. 2011 Dec;55(6):1391-9
pubmed: 21703208
World J Gastroenterol. 2019 Oct 7;25(37):5676-5686
pubmed: 31602167